Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 12 publications
Inotuzumab ozogamicin in paediatric very high risk first B-cell acute lymphoblastic leukaemia relapse (ITCC-059): a multicentre, single-arm, phase 2 trial.
Journal: The Lancet. Haematology
Published: January 27, 2026
Inotuzumab ozogamicin combined with chemotherapy in pediatric B-cell precursor CD22+ acute lymphoblastic leukemia: results of the phase IB ITCC-059 trial.
Journal: Haematologica
Published: October 09, 2023
Inotuzumab ozogamicin as single agent in pediatric patients with relapsed and refractory acute lymphoblastic leukemia: results from a phase II trial.
Journal: Leukemia
Published: January 27, 2022
Inotuzumab Ozogamicin for Relapsed/Refractory Acute Lymphoblastic Leukemia in the INO-VATE Trial: CD22 Pharmacodynamics, Efficacy, and Safety by Baseline CD22.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: June 21, 2020
Glasdegib plus intensive/nonintensive chemotherapy in untreated acute myeloid leukemia: BRIGHT AML 1019 Phase III trials.
Journal: Future oncology (London, England)
Published: September 14, 2019
Inotuzumab ozogamicin versus standard of care in Asian patients with relapsed/refractory acute lymphoblastic leukemia.
Journal: International journal of hematology
Published: June 27, 2019
Prognostic implications of cytogenetics in adults with acute lymphoblastic leukemia treated with inotuzumab ozogamicin.
Journal: American journal of hematology
Published: July 17, 2018
Efficacy and safety analysis by age cohort of inotuzumab ozogamicin in patients with relapsed or refractory acute lymphoblastic leukemia enrolled in INO-VATE.
Journal: Cancer
Published: October 16, 2017
Hepatic adverse event profile of inotuzumab ozogamicin in adult patients with relapsed or refractory acute lymphoblastic leukaemia: results from the open-label, randomised, phase 3 INO-VATE study.
Journal: The Lancet. Haematology
Published: March 22, 2017
Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia.
Journal: The New England journal of medicine
Published: June 14, 2016
Showing 1-12 of 12
Last Updated: 09/26/2026